The stock has a 36-month beta value of 0.05. Opinions on the stock are mixed, with 0 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for AYTU is 5.99M, and at present, short sellers hold a 12.36% of that float. On June 04, 2025, the average trading volume of AYTU was 1.18M shares.
AYTU) stock’s latest price update
Aytu BioPharma Inc (NASDAQ: AYTU) has experienced a decline in its stock price by -12.92 compared to its previous closing price of 1.78. However, the company has seen a fall of -21.72% in its stock price over the last five trading days. seekingalpha.com reported 2025-05-14 that Aytu BioPharma, Inc. (Aytu ) Q3 2025 Earnings Conference Call May 14, 2025 4:30 PM ET Company Participants Robert Blum – Investor Relations, Lytham Partners Josh Disbrow – Chief Executive Officer Ryan Selhorn – Chief Financial Officer Conference Call Participants Naz Rahman – Maxim Group Operator Greetings. And welcome to the Aytu BioPharma Fiscal 2025 Q3 Earnings Call.
AYTU’s Market Performance
AYTU’s stock has fallen by -21.72% in the past week, with a monthly rise of 18.33% and a quarterly rise of 23.02%. The volatility ratio for the week is 6.01% while the volatility levels for the last 30 days are 16.17% for Aytu BioPharma Inc The simple moving average for the past 20 days is -9.89% for AYTU’s stock, with a -10.05% simple moving average for the past 200 days.
Analysts’ Opinion of AYTU
Many brokerage firms have already submitted their reports for AYTU stocks, with Cantor Fitzgerald repeating the rating for AYTU by listing it as a “Overweight.” The predicted price for AYTU in the upcoming period, according to Cantor Fitzgerald is $11 based on the research report published on March 30, 2021 of the previous year 2021.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see AYTU reach a price target of $3. The rating they have provided for AYTU stocks is “Buy” according to the report published on May 29th, 2020.
AYTU Trading at 13.73% from the 50-Day Moving Average
After a stumble in the market that brought AYTU to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -52.01% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at AYTU starting from Disbrow Joshua R., who purchase 15,000 shares at the price of $1.30 back on Feb 28 ’25. After this action, Disbrow Joshua R. now owns 86,591 shares of Aytu BioPharma Inc, valued at $19,500 using the latest closing price.
Stock Fundamentals for AYTU
Current profitability levels for the company are sitting at:
- -0.06 for the present operating margin
- 0.69 for the gross margin
The net margin for Aytu BioPharma Inc stands at 0.02. The total capital return value is set at -0.07. Equity return is now at value 3.29, with 0.85 for asset returns.
Based on Aytu BioPharma Inc (AYTU), the company’s capital structure generated 0.05 points at debt to capital in total, while cash flow to debt ratio is standing at -2.98. The debt to equity ratio resting at 0.05. The interest coverage ratio of the stock is -3.29.
Currently, EBITDA for the company is -1.01 million with net debt to EBITDA at -5.16. When we switch over and look at the enterprise to sales, we see a ratio of -0.1. The receivables turnover for the company is 1.93for trailing twelve months and the total asset turnover is 0.56. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.03.
Conclusion
To sum up, Aytu BioPharma Inc (AYTU) has seen a mixed performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
